Angela Qu, MD, PHD’s Post

Hear from Parexel experts at the American Society for Clinical Pharmacology & Therapeutics 2024 Annual Meeting! Don’t miss our Learning Lab session on "Unlocking Clinical Trial Success," where Angela Qu and Ana Novakovic will share insights and case studies aimed at optimizing study efficacy through data-driven decision-making. Follow the link below for more information or to schedule a meeting with Parexel at ASCPT! https://lnkd.in/gVe-r5x2 #ASCPT2024 #ClinicalResearch #ClincalPharmacology #TranslationalScience

Please join our discussion on the complexities of clinical pharmacology. Where we are combining not just study designs but also healthy volunteers with patients in Phase I studies. These hybrid models require an experienced team with resources and facilities capable of handling both types of study participants. #ascpt #hybridmodel #phase1b

Check out what you missed in our latest webinar, The Basics of Drug-Drug Interaction Studies 📝 Expert tips on designing protocols 🔍 How to interpret results like a pro 💊 Everything you need to know about DDI trials 📚 Exclusive case study from SGS Clinical Pharmacology Unit Catch the full recording and level up your knowledge 👉 https://lnkd.in/eRYrxnMm #clinicalresearch #drugsafety #patientsafety

TL;DR: 1st levothyroxine MIPD for use in primary care suggests higher accuracy than conventional age or weight-based methods (using retrospective data + clinical simluation trials) American Society for Clinical Pharmacology & Therapeutics: ➡ https://bit.ly/3Vurpgu | #ModelInformedPrecisionDosing #MIPD #PresicionMedicine #PrecisionDosing #Levothyroxine

Two weeks today Altasciences will be hosting the symposium 'Current Trends for Efficient Drug Development' on Campus. Speakers include Robert Wilson, Drug Development and Clinical Pharmacology Director, at Healx who will share details of incorporating AI in drug discovery. Other topics will include regulatory pathways to conduct first-In-human trials in Canada and the journey of an obesity compound that has been 20 years in the making. Registration is essential - https://ow.ly/P69f50RFGlt

Empower yourself with the knowledge and tools to navigate the complexities of drug-drug interactions in drug development successfully. In this webinar, you'll: ✔️ Learn to choose which interactions to examine when designing protocols ✔️ Acquire skills to interpret and analyze data from these trials ✔️ Explore real case studies from our Clinical Pharmacology Unit. Join expert Lotte Verwilligen in next week's webinar 👉 https://lnkd.in/eRYrxnMm #clinicalresearch #drugsafety #patientsafety

Despite PGx testing being instituted into standard clinical workflows, genotype-guided recommendations are not being adopted by all prescribers during treatment. To change standard of care, professional society clinical practice guidelines would need to endorse these recommendations; however, there has been hesitancy to do so without prospective randomized controlled trial data. How do we demonstrate evidence for implementation in cases where randomized controlled trials are not practical? Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02QDLqb0 | #PrecisionMedicine #PGx #Pharmacogenomics #Pharmacology Indiana University School of Medicine

In H1 of 2024, the number of ADCs in development surged by 21%. Despite this growth, deals in the ADC space plummeted from $167B to $47B this year. Only 4 ADCs progressed from phase 1 and phase 1/2, highlighting the industry's struggle with dosing regulations from Project Optimus. Calling all ADC developers in PK/PD, Bioanalysis, Clinical Pharmacology, or DMPK! Let's connect and discuss the upcoming ADC PK & Clinical Pharmacology Summit agenda. Simplify drug development by embracing quantitative pharmacology. Streamline your R&D journey with a roadmap from discovery to clinical application. PS - Hugo also loves ADCs!

This seems like an informative workshop in clinical pharmacology (May 8-9). I am very interested in Session 2 on considerations for specific patient subpopulations and Session 3 applications for rare disease drug development. Check it out at: https://lnkd.in/gx6vafqw #FDA #ClinicalPharmacology

We've had a great time at SOT! If you're working in cardiac safety pharmacology, make sure to download our exciting concept discussion pieces. At Axol Bioscience, we've been looking into the key questions of utility and relevance for iPSC-derived cardiotoxicity models. We've therefore produced two discussion documents based on our research in this space: 1. Our ongoing work licensing an innovative protocol developed by a team at The Crick Institute, which aims to produce purer populations of left ventricular cardiomyocytes https://hubs.la/Q02prMJz0 2. The identification of a metabolic maturation media to enhance cardiomyocyte maturity https://hubs.la/Q02prFW30 We were delighted to see such a positive response to these documents at SOT, so we've made them available to download by clicking the links above. If you have any questions or would like to discuss how we could unlock iPSC technology for your cardiotoxicity projects, please get in touch as operations@axolbio.com #iPSCs #SOT #cardiotoxicity #neurotoxicity #CiPA #DrugDiscovery